Regeneron Prescription drugs for the acquisition of 23Andme and its knowledge for 256 million US {dollars}

A look at the 23Andme headquarters in Sunnyvale, California, on March 25, 2025.

Tayfun Coskun | Anadolu Getty Images

Regeneron pharmaceuticals On Monday it announced that “essentially all” from 23andmes will acquire assets for 256 million US dollars.

The drug manufacturer took part in an insolvency auction for 23Andme, a once-flying genetic test company that was submitted in March for bankruptcy protection in Chapter 11. According to a press release, Regeneron buys 23andmes genome service, total and research services lines.

“We believe that we can help 23Andme to deliver and build up their mission to help people learn about their own DNA and improve their personal health, and at the same time to improve regenerons to improve health and well -being of many,” said Dr. George Yancopoulos, President of Regeneron in a statement.

Regeneron will not buy the company's telemedicine subsidiary, Lemonaid Health.

The deal is still subject to the approval of the US insolvency court for the eastern district of Missouri. Provided that according to the publication, it is expected to be closed in the third quarter of this year.

23Andme shot into the mainstream at home because of his DNA test kits, which gave the customer an insight into their family history and genetic profiles. In 2021, the five -time CNBC Disruptor 50 Company went to the stock exchange with a merger with a special company for purposes. At its climax, 23Andme had a value of around 6 billion US dollars.

The company tried to generate recurring earnings and to face the public for viable research and therapists, and it was plagued by data protection concerns, since Hacker accessed the information from almost 7 million customers in 2023.

In his bankruptcy proceedings, 23Andme asked all bidders to comply with their data protection guidelines, and a judicial, independent “independent ombudsman” The consumer privacy will evaluate the deal.

Several legislators and civil servants, including the Federal Trade Commission, had expressed concerns about the security of the genetic data of consumers in the course of 23Andme's sales process. The data protection officer will submit a report on the acquisition to the court by June 10th.

“We are pleased to have reached a transaction that maximizes the value of the business and enables 23Andme mission to continue living, and at the same time to maintain critical protection in relation to privacy, the selection and approval of the customer with regard to their genetic data,” said Mark Jensen, 23andmes CEO.

Clock: 23Andme in autumn